Faron Pharmaceuticals extends funding agreement with IPF
30th Apr 2024 16:33
(Sharecast News) - Faron Pharmaceuticals announced on Tuesday that it has extended its agreement with lender IPF to ensure continued financial support as it progressed towards securing longer-term funding.
Read moreFaron Pharmaceuticals CFO stands down
15th Apr 2024 09:36
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals revealed on Monday that chief financial officer James O'Brien would be leaving the group to "pursue another career opportunity".
Read moreFaron Pharmaceuticals taps Juho Jalkanen for CEO
8th Apr 2024 09:17
(Sharecast News) - Biopharmaceutical company Faron Pharmaceuticals named Dr Juho Jalkanen as its next chief executive officer on Monday.
Read moreFaron shares jump on encouraging trial data
18th Mar 2024 14:14
(Sharecast News) - Faron Pharmaceuticals announced further encouraging data from the first phase of its 'BEXMAB' trial on Monday, targeting higher-risk (HR) myelodysplastic syndrome (MDS) patients who had failed prior hypomethylating agent (HMA) treatment.
Read moreFaron Pharmaceuticals reports year of clinical progress
13th Mar 2024 11:52
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant overall response rates seen in both previously hypomethylating agent (HMA)-failed and higher-risk myelodysplastic syndrome (MDS) patient populations in the phase one part of the BEXMAB study.
Read moreFaron Pharmaceuticals shores up cash with EUR 3.2m convertible loans
4th Mar 2024 10:40
(Sharecast News) - Faron Pharmaceuticals announced on Monday that it has successfully secured binding commitments for convertible loans totalling €3.2m from a select group of existing shareholders.
Read moreFaron launches second phase of leukaemia treatment trial
9th Jan 2024 12:36
(Sharecast News) - Faron Pharmaceuticals has initiated phase two of the BEXMAB trial, it announced on Tuesday, marking a significant milestone in its cancer treatment development programme.
Read moreFaron unveils promising antibody study results
11th Dec 2023 13:22
(Sharecast News) - Faron Pharmaceuticals unveiled promising phase one data from its BEXMAB study in myeloid malignancies during the 65th American Society of Hematology (ASH) annual meeting, it announced on Monday.
Read moreFaron publishes cancer immunotherapy study findings
7th Dec 2023 11:01
(Sharecast News) - Faron Pharmaceuticals announced the publication of the comprehensive findings from the groundbreaking phase one and two 'MATINS' trial of bexmarilimab on Thursday - its humanised monoclonal anti-CLEVER-1 antibody aimed at transforming the landscape of anticancer immunotherapies.
Read moreFaron reveals details of next stage of bexmarilimab study
6th Nov 2023 10:31
(Sharecast News) - Faron Pharmaceuticals announced on Monday that, following guidance from the US Food and Drug Administration (FDA), the initial indication for phase two advancement in the study investigating bexmarilimab in combination with standard of care, would focus on hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndromes (MDS).
Read moreFaron Pharmaceuticals upbeat on latest data in blood cancer trials
11th Oct 2023 14:53
(Sharecast News) - Faron Pharmaceuticals announced encouraging updated data from its ongoing phase one and two 'BEXMAB' study into relapsed or refractory (r/r) acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) treatments on Wednesday.
Read moreFaron Pharmaceuticals names interim chief medical officer
21st Sep 2023 14:45
(Sharecast News) - Cancer immunotherapy-focussed biopharmaceutical firm Faron Pharmaceuticals named Dr Birge Berns as its interim chief medical officer on Thursday, with the transition becoming effective on 22 September, with Dr Berns operating from the UK.
Read moreFaron Pharmaceuticals names James O'Brien as CFO
29th Mar 2023 09:38
(Sharecast News) - Drug discovery and development company Faron Pharmaceuticals has tapped James O'Brien to take over as its new chief financial officer.
Read moreFaron Pharmaceuticals gets positive feedback from FDA meeting
22nd Mar 2023 17:12
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals said on Wednesday that it had received positive feedback from the US Food and Drug Administration (FDA) on the development of its precision immunotherapy asset 'bexmarilimab'.
Read moreFaron upbeat on updated data from cancer treatment study
23rd Feb 2022 13:37
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced updated survival data from the phase 1 and 2 study investigating the safety and efficacy of 'bexmarilimab' on Wednesday.
Read more